BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 3480796)

  • 1. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin.
    Speciale A; Stefani S; Caccamo F; Nicolosi VM; Nicoletti G
    Drugs Exp Clin Res; 1987; 13(9):555-61. PubMed ID: 3480796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin.
    Speciale A; Stefani S; Caccamo F; Nicolosi VM; Nicoletti G
    Chemioterapia; 1987 Feb; 6(1):17-22. PubMed ID: 3470153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility in vitro of gram-positive aerobe and anaerobe bacteria to ofloxacin.
    Debbia E; Mannelli S; Gianrossi G; Schito GC
    Drugs Exp Clin Res; 1987; 13(4):213-7. PubMed ID: 3304918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ofloxacin: antibacterial activity, induction of resistance and killing curves.
    Husson MO; Izard D; Bryskier A; Leclerc H
    Chemioterapia; 1985 Aug; 4(4):278-83. PubMed ID: 3863716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
    Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C
    Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
    Croize J; Le Noc P; Bryskier A; Robert J
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of pefloxacin against gram-negative and gram-positive bacteria in comparison with other antibiotics.
    Debbia E; Schito GC; Nicoletti G; Speciale A
    Chemioterapia; 1987 Oct; 6(5):319-23. PubMed ID: 3480779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial activity of norfloxacin against 1700 relatively resistant clinical isolates.
    Qadri SM; Lee G; Brodie L
    Drugs Exp Clin Res; 1989; 15(8):349-53. PubMed ID: 2598776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro activity of norfloxacin against gram-positive and gram-negative organisms from recent clinical isolates].
    Mancini C; Brenciaglia MI; Ghezzi MC; Giordano A; Nazzari C; Cipriani P
    Boll Ist Sieroter Milan; 1985; 64(4):289-93. PubMed ID: 3935135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
    Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro activity of seven gyrase inhibitors of a group of heterocyclic carbonic acids against nonfermenting gram negative rods (nonfermenters)].
    Grimm H
    Arzneimittelforschung; 1985; 35(3):570-2. PubMed ID: 2986655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiological characterization of dactimicin: antibacterial activity towards gram-positive and gram-negative bacteria.
    Stefani S; Debbia EA; Schito GC; Russo G
    Drugs Exp Clin Res; 1989; 15(3):119-23. PubMed ID: 2752910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Susceptibility in vitro to certain quinolines of gram-negative bacteria and gram-positive cocci causing urinary tract infections].
    Mróz E; Jankowski S; Bartelmus J; Grzybek-Hryncewicz K; Ruczkowska J; Starek J; Boratyńska M
    Med Dosw Mikrobiol; 1993; 45(1):115-8. PubMed ID: 8231429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro fluoroquinolone resistance in ocular bacterial isolates].
    Sun XG; Wang ZQ; Li R; Chen L; Jin XY; Luo SY
    Zhonghua Yan Ke Za Zhi; 2003 Mar; 39(3):163-6. PubMed ID: 12880574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity of ciprofloxacin, ofloxacin and pefloxacin against resistant clinical isolates.
    Periti P; Mazzei T; Nicoletti P
    Chemioterapia; 1987 Apr; 6(2):75-8. PubMed ID: 3474081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.